The inaugural bioprocessing and manufacturing event, bioLIVE, taking place between 9 and 11 October in Madrid, will introduce a biologics manufacturing and processing league table, ranking the perception of the world’s largest biologics markets for ‘overall quality’, ‘growth potential’, ‘innovation’ and ‘ability to meet future capacity constraints’.
Madrid
“Biologics capacity is growing quickly and will increase by nearly 40% over the next four years,” said Rutger Oudejans, brand director at UBM for bioLIVE. “Asian and European countries are building more facilities, which is reducing the USA’s overall market share of capacity. What no one has yet evaluated is the relative perceived strengths of each region. The perception of each country will undoubtedly be a factor in realising its growth potential.”
Creation of this list will allow for evaluation of the consequences for the supply chain — with increasing numbers of bio facilities around the world, the perception of being able to meet future demand could prove integral in investment decisions. Additionally, it will show which markets are seen to have the best potential growth both domestically and for exports.
This global biopharma country ranking builds on the small molecule ranking that was created last year by event organisers UBM. In last year’s ranking the traditional economies of the USA, Germany and Japan were perceived as the strongest but with the rapid emergence of ‘bio regions’ this year’s biopharma ranking could see countries like Korea, China and Singapore ranking higher for large molecule manufacturing.
Furthermore, through evaluating the potentially geopolitical and supply chain risks in newer regions, as well as the knowledge of bio professionals, it may be possible to get a picture of certain countries being seen as exceptional for capacity and production, and others for knowledge and innovation.
A key consideration when launching bioLIVE was the potential benefits of integrating small and large molecules industries. However, with an increasingly globalised supply chain, it is important that the industry can centralise and share learning.
“One of the great successes of the small molecules space has been the internationalisation of the supply chain, and we want to bring this experience and couple it with industry analysis from prominent experts, and new original research, so that we can better inform the bio community on the opportunities available. To sustain the next wave of growth, the industry will need to meet new partners, but also, access insights and content to know how best to work with new customers. With this in mind, bioLIVE will be a mixture of biotechs, big pharma and service providers, coupled with an extensive learning programme for bio processing and manufacturing professionals,” added Oudejans.